|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-06
|
$660,173
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
MOTILITY AND INVASION
|
5P01CA100324-16
|
$2,028,990
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
20/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project
|
5U01DK048349-26
|
$68,181
|
CRANDALL, JILL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-05
|
$346,525
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
PI3K Isoform Dependence in Adult Hematopoiesis and Myeloid Leukemia
|
5R01CA196973-03
|
$415,736
|
GRITSMAN, KIRA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Use of focused ultrasound to increase melanoma immunogenicity and inhibit tumor-induced T cell tolerance
|
1R01CA226861-01
|
$382,013
|
MACIAN, FERNANDO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-19
|
$417,500
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Imaging and Radiation Oncology Core (IROC) Group
|
5U24CA180803-05
|
$8,285,739
|
FOLLOWILL, DAVID
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Young Investigator travel support for the 2016 through 2020 APS Annual Scientific Meetings
|
5R13AT009161-03
|
$5,000
|
PRICE, THEODORE
|
AMERICAN PAIN SOCIETY
|
|
Genetic Analysis of Myeloproliferative Disease
|
5R01CA076167-15
|
$307,800
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
|
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
|
5R01CA168912-05
|
$320,588
|
HE, YUKAI
|
AUGUSTA UNIVERSITY
|
|
Role of IRF8 in Tumor Rejection and Suppression
|
5R01CA133085-09
|
$307,800
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Chemotherapy-induced MDSCs and antitumor immunity
|
5R01CA215523-02
|
$347,700
|
ZHOU, GANG
|
AUGUSTA UNIVERSITY
|
|
Proteogenomic Translational Research Center for Clinical Proteomic
|
5U01CA214116-02
|
$1,372,508
|
RODLAND, KARIN
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
An ultrasensitive targeted mass spectrometry system for proteomics analysis of single cells
|
1R21CA223715-01
|
$263,953
|
SHI, TUJIN
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
A novel N-Ras pathway driving DCIS to basal-like breast cancer
|
1R21CA226567-01
|
$212,055
|
CHANG, ERIC
|
BAYLOR COLLEGE OF MEDICINE
|
|
MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS
|
5U01CA214125-02
|
$1,413,657
|
ELLIS, MATTHEW
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Sox9/NFIA Transcriptional Network In Malignant Glioma
|
5K01CA190235-04
|
$140,400
|
GLASGOW, STACEY
|
BAYLOR COLLEGE OF MEDICINE
|
|
The ATM/E2F1 Pathway in DNA Damage and Growth Control
|
5R01CA100857-14
|
$356,625
|
LIN, WEEI-CHIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
MOLECULAR DISSECTION OF SEIZURE MICROENVIRONMENT IN MALIGNANT GLIOMA
|
1R01CA223388-01
|
$632,130
|
NOEBELS, JEFFREY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Racial Disparity in Bladder Cancer and Identification of Altered Metabolism in African American Compare to European Bladder Cancer
|
5R01CA220297-02
|
$365,246
|
PUTLURI, NAGIREDDY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Wnt pathway dynamics in breast cancer metastasis
|
5K22CA207463-02
|
$188,042
|
ROARTY, KEVIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Engineering Antibody Drug Conjugates To Target P53-Defective Triple Negative Breast Cancer
|
5R21CA213535-02
|
$207,797
|
WANG, JIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Development of microRNA Biomarkers For Noninvasive Detection of Colorectal Cancer
|
5R01CA184792-04
|
$347,517
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Reducing risk of Anthracycline-related heart failure after childhood cancer
|
5R01CA196854-04
|
$604,525
|
ARMENIAN, SARO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy
|
5R01CA197359-04
|
$388,875
|
BERLIN, JACOB
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
The role and functional mechanism of TET1 in MLL-rearranged leukemia
|
5R01CA178454-07
|
$369,725
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple Myeloma
|
5R01CA212119-02
|
$580,951
|
CHEN, YUAN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Epigenomic Biomarkers to Manage Thyroid Nodule Overdiagnosis and Overtreatment
|
1R21CA223367-01
|
$242,633
|
HAHN, MARIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia
|
5R01CA213131-02
|
$430,377
|
KORTYLEWSKI, MARCIN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
|
5R01CA213138-02
|
$395,738
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Metabolic basis of B cell lineage leukemia relapse
|
5R35CA197628-03
|
$1,035,561
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Development and validation of a computational prediction model for exogenous neural stem cell migration to sites of brain tumors
|
1R03CA216142-01A1
|
$86,500
|
ROCKNE, RUSSELL
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting the ARHGAP25 pathway in acute myelogenous leukemia stem cells
|
5K08CA201591-02
|
$169,560
|
WANG, LEO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Control of tumor growth and metastasis by the cytokine TSLP
|
5R01CA182783-05
|
$362,503
|
ZIEGLER, STEVEN
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect
|
5R01CA212605-02
|
$517,798
|
BOUSSIOTIS, VASSILIKI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Complex Role of HSF1 in Breast Cancer
|
5R01CA176326-05
|
$355,719
|
CALDERWOOD, STUART
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Overcoming resistance to tyrosine kinase inhibitors in lung cancer
|
5R01CA169259-06
|
$361,049
|
KOBAYASHI, SUSUMU
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Isolation and Assessment of Blood-Circulating Cancer Exosomes with LSS and SERS Lab on a Chip Optical Spectroscopic Instrument
|
1R01CA218382-01A1
|
$668,549
|
PERELMAN, LEV
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Discussions of Prognosis and Stopping Cancer Screening in Older Adults
|
5R21CA212386-02
|
$189,709
|
SCHONBERG, MARA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
ANTAGONISM OF VEGA-DRIVEN ANGIOGENESIS
|
5R01CA077357-09
|
$303,039
|
SENGER, DONALD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Generation of Antiangiogenic Activity for Cancer Treat.
|
5R01CA098948-05
|
$270,081
|
SUKHATME, VIKAS
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Functional analysis of a tissue context-dependent role for beta-TRCP in lipid metabolism and tumorigenesis
|
9R01CA229307-05A1
|
$374,063
|
WEI, WENYI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Novel Uses of PI3K-inhibitors for the Treatment of advanced PIK3CA-mutant Breast Cancer
|
1R01CA226776-01
|
$400,313
|
WULF, GERBURG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood
|
5R44CA213595-02
|
$712,071
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Long Acting VEGF BInding Proteins for Treating Cancer
|
5R44CA099217-03
|
$335,148
|
Cox, George
|
BOLDER BIOTECHNOLOGY, INC.
|
|
Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma
|
5R01CA196703-04
|
$404,888
|
CHIARLE, ROBERTO
|
BOSTON CHILDREN'S HOSPITAL
|
|
Role of Insulin Receptor Substrates in Kras-driven lung cancer
|
5R01CA211944-02
|
$404,888
|
KALAANY, NADA
|
BOSTON CHILDREN'S HOSPITAL
|
|
CXCR3-B-mediated novel growth-inhibitory signals in breast cancer cells
|
1R03CA215926-01A1
|
$88,500
|
PAL, SOUMITRO
|
BOSTON CHILDREN'S HOSPITAL
|
|
Structural mechanisms underlying latency and activation of GDF8
|
5R01CA210920-03
|
$394,594
|
SPRINGER, TIMOTHY
|
BOSTON CHILDREN'S HOSPITAL
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|